

# Scriptaid

## Catalog No: tcsc1014



### Available Sizes

**Size:** 10mg

**Size:** 50mg



### Specifications

**CAS No:**

287383-59-9

**Formula:**

$C_{18}H_{18}N_2O_4$

**Pathway:**

Autophagy;Epigenetics;Cell Cycle/DNA Damage

**Target:**

Autophagy;HDAC;HDAC

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 150$  mg/mL (459.63 mM)

**Alternative Names:**

Scriptide;GCK1026

**Observed Molecular Weight:**

326.35


## Product Description

Scriptaid is a potent **histone deacetylase (HDAC)** inhibitor, used in cancer research.

IC<sub>50</sub> & Target: HDAC<sup>[1]</sup>

**In Vitro:** Scriptaid (1 µg/mL) treatment inhibits cell growth in breast cancer cell lines, results in increased accumulation of both acetyl H3 and acetyl H4 proteins in MDA-MB-231, MDA-MB-435, and Hs578t cells. Scriptaid also inhibits cell growth of MDA-MB-231, MDA-MB-435, and Hs578t cell lines, with IC<sub>50</sub>s of 0.5-1.0 µg/mL. Scriptaid (0.1-1.0 µg/mL) induces ER and PR mRNA expression in a dose dependent manner; when it is combined with AZA, they enhance ER expression and induce a functional ER protein<sup>[1]</sup>. Scriptaid and SAHA preferentially inhibit the Class I histone deacetylases, hdac1, 2, and 3. Scriptaid is a potent anti-*T. gondii* compound with low cytotoxicity, and the IC<sub>50</sub> is 39 nM. Scriptaid has atypical effects in *T. gondii* infected HS68 cells<sup>[2]</sup>. Scriptaid inhibits the growth of HeLa cells with IC<sub>50</sub> of 2 µM at 48 h in a dose-dependent manner. Scriptaid also affects cell-cycle and apoptosis<sup>[3]</sup>.

**In Vivo:** Scriptaid (3.5 µg/g mouse, i.p.) clearly inhibits tumor growth in a xenograft mouse model<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!